Top stories Merpel hopes to write in 2014 from ipkitten.blogspot.com IPKAT ADVISORY: THE CONTENTS OF THIS BLOGPOST MAY BE OFFENSIVE TO SOME READERS, PARTICULARLY THOSE WITH NO SENSE OF HUMOUR, OR WITH A DIFFERENT SENSE OF HUMOUR TO MERPEL'SInspired by Neil's post ... Share via E–mail | Twitter | Facebook
The wounded patent survived, was only just infringed, but no injunction from ipkitten.blogspot.com New Year's Day is perhaps not an auspicious time on which to post about a technically detailed patent case, but this Kat has finally had a chance to complete a review of this decision ...
Share via E–mail | Twitter | Facebook
Appellant prevails in Ex parte Halstead from ipbiz.blogspot.com From
Ex parte HalsteadA footnote indicates that the Examiner cited the wrong part of 35 USC 102:
The Examiner rejects claims 20-25 and 32-37 under 35 U.S.C. § 102(b) (Ans. 3-4). We ... Share via E–mail | Twitter | Facebook
Appellant loses on obviousness in Ex parte Lee from ipbiz.blogspot.com The appellant in
Ex parte Lee lost: On the record before us, we conclude that the Examiner has not erred
in rejecting claims 1-13 under 35 U.S.C. §103(a).
Lovin is cited
Appellant ... Share via E–mail | Twitter | Facebook
Zuvachem's US 8,609,385 on a method to make isoprene from genetically engineered cyanobacteria from ipbiz.blogspot.com The first claim:
A method for the production of isoprene, the method comprising: culturing a genetically engineered cyanobacterium comprising a nucleic acid encoding a plant isoprene synthase in a bioreactor to produce isoprene,
said nucleic ... Share via E–mail | Twitter | Facebook
Top Stories of 2013: #7 to #10 from www.patentdocs.org By Donald Zuhn -- Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on ...
Share via E–mail | Twitter | Facebook